Regulus Therapeutics (United States)

Regulus Therapeutics (United States)

Regulus Therapeutics Inc. or Regulus is a clinical stage biopharmaceutical company focused on the development of first-in-class drugs that target microRNAs to treat a broad range of diseases. Regulus was established in September 2007 by Alnylam Pharmaceuticals and Isis Pharmaceuticals. Derived from Wikipedia licensed CC-BY-SA.

Open Access statistics for Regulus Therapeutics (United States), United States, covering academic research published from 2008 to 2023. Read More.


Open Access Percentage

56%


Total
Publications

150


Total Open
Publications

84


Total
Citations

18K


Open Access
Percentage

56%


Total
Publications

150


Total Open
Publications

84


Total
Citations

18K

Wikipedia

Website

download

Breakdown

8% 31% 17% 44%

Publisher Open

8%

Both

31%

Other Platform Open

17%

Closed

44%

Percentage of Open Access over time

0%10%20%30%40%50%60%70%80%90%100%
2008200920102011201220132014201520162017201820192020202120222023

Publisher Open

Both

Other Platform Open

Closed

Volume of Open Access over time

024681012141618202224Total Publications
2008200920102011201220132014201520162017201820192020202120222023

Open

Closed

Publisher Open

34%OA Journal

OA Journal 34%

20

Hybrid 30%

18

No Guarantees 36%

21

Other Platform Open

Domain 90%

65

Institution 31%

22

Public 22%

16

Other Internet 17%

12

Preprint 6%

4

Other Platform Locations

Name

Platform Type

Publications

PubMed Central
Domain
65
Europe PMC
Domain
56
DOI
Other Internet
28
Semantic Scholar
Public
10
Figshare
Public
9
California Institute of Technology - CaltechAUTHORS
Institution
7
California Digital Library - eScholarship
Other Internet
6
Harvard University - Digital Access to Scholarship at Harvard (DASH)
Institution
5
Le Centre pour la Communication Scientifique Directe - HAL - Inserm
Institution
4
bioRxiv
Preprint
4
1 / 3

Data updated 25 January 2024

Share

Share

Share